By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Medivation, Inc. 

525 Market Street
36th Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


SEARCH JOBS

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at http://www.medivation.com/

Key Statistics


Email: info@medivation.com
Ownership: Public

Web Site: Medivation, Inc.
Employees: 18
Symbol: MDVN
 





Collaborations

Pfizer 





Company News
Medivation, Inc. (MDVN) Voted Three Years In A Row Among Top Workplaces In The San Francisco Bay Area 6/30/2015 12:25:33 PM
Cheryl Cohen, Former Medivation, Inc. (MDVN) Chief Commercial Officer, Joins CytRx Corporation (CYTR) Board Of Directors 6/24/2015 7:58:12 AM
Medivation, Inc. (MDVN) To Redeem Outstanding Convertible Notes Due 2017 6/23/2015 1:31:09 PM
Medivation, Inc. (MDVN) And Astellas Announce Enrollment Of The First Patients In Advanced Prostate Cancer Outcomes Registry 6/17/2015 11:35:34 AM
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Announce Enrollment Of The First Patients In Advanced Prostate Cancer Outcomes Registry 6/17/2015 6:29:37 AM
ASCO15: Medivation, Inc. (MDVN) Release: New Enzalutamide Data In Triple-Negative Breast Cancer Presented At The 2015 American Society of Clinical Oncology Annual Meeting 6/2/2015 1:13:45 PM
Medivation, Inc. (MDVN) Names Andrew Powell General Counsel 5/29/2015 9:44:52 AM
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting 5/18/2015 8:11:15 AM
Medivation, Inc. (MDVN) Release: New Enzalutamide Data In Triple-Negative Breast Cancer To Be Presented At The 2015 ASCO Annual Meeting 5/15/2015 11:29:14 AM
Medivation, Inc. (MDVN) Reports First Quarter 2015 Financial Results 5/8/2015 10:12:26 AM
12345678910...
//-->